Compare CVS Health Corp (CVS) vs Innovative Industrial Properties Inc (IIPR) Price & Performance

CVS Health trades at $94.12, down 1.62% today, but maintains strong analyst support with 33 buy ratings and a $115.90 consensus price target. The company delivered three consecutive earnings beats in 2026, with Q2 EPS of $2.58 beating expectations by 38%. Technical indicators show mixed signals with bullish oscillators but bearish moving averages, while fundamentals reveal solid revenue growth to $402.07B in 2025 despite margin compression.

CVS presents a compelling value opportunity with attractive valuation ratios (P/S: 0.29, P/B: 1.5) and strong institutional confidence. Near-term catalysts include continued Aetna recovery and healthcare services expansion, though risks include 2027 PBM pressures and margin volatility. The stock offers 23% upside to analyst targets with defensive healthcare positioning.

IIPR trades at $58.22, up 1.29% on the day, with a bearish technical signal despite oversold RSI readings near 29. The stock shows mixed earnings performance, beating estimates in Q2 2026 but missing in Q1, with Q3 results pending. Revenue declined to $266 million in 2025, though net margins remain strong at 52.27%. A recent dividend of $1.90 was declared, payable in July 2026. Analyst sentiment is cautious with a Hold-heavy consensus, while institutional activity includes a significant position increase by Arrowstreet Capital.

The outlook for IIPR balances high profitability and a solid balance sheet against revenue headwinds and tenant distress risks. Investment appeal lies in its attractive valuation (P/E of 13.05, P/B below 1) and high dividend yield, but caution is warranted due to declining cash flow, bearish technical trends, and sector-specific regulatory uncertainties. The stock may offer value for income-focused investors if operational stability improves.